Faraz Ali, Tenaya CEO
Tenaya bags $75M from stock sale as it prepares to put a gene therapy for heart disease into the clinic
In its Q3 update, Tenaya Therapeutics told investors that it’s reprioritizing the pipeline to extend the runway until 2024 and focus its three lead programs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
